Download PDF
Arzneimittelforschung 2011; 61(1): 23-31
DOI: 10.1055/s-0031-1296164
Antidiabetics
Editio Cantor Verlag Aulendorf (Germany)

Novel liquid chromatographic method for simultaneous estimation of pioglitazone and glimepiride in rat plasma by solid phase extraction: application to preclinical pharmacokinetic studies

Prashant B Musmade
1   Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
,
Kranti B Talole
1   Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
,
Praful B Deshpande
1   Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
,
Arumugam Karthik
1   Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
,
Shriram M Pathak
1   Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
,
Sureshwar Pandey
2   Schools of Pharmacy, The University of the West Indies, St. Augustine, Trinidad, Tobago
,
Nayanabhirama Udupa
1   Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
› Author Affiliations
Further Information

Publication History

Publication Date:
28 November 2011 (online)

    Permissions and Reprints

Abstract

The need for a reliable bioanalytical method is of primary importance during preclinical studies. The aim of the present study was simultaneous determination of pioglitazone (CAS 111025-46-8) (PIO) and glimepiride (CAS 93479-97-1) (GLM) in plasma of rats. A high-performance liquid chromatographic method has been developed and validated using C18 column and UV detector. A mobile phase composed of acetonitrile and ammonium acetate buffer pH 4.5 in the ratio of 55 : 45%. The plasma samples clean-up was carried out using solid phase cartridges. The method was in the linear range of 50–8000 ng/mL for PIO and 50-2000 ng/mL for GLM. The coefficient of regression was found to be ≥ 0.99. Precision and accuracy were within the acceptable limits, as indicated by relative standard deviation varying from 1.5 to 6.1% for PIO and 3.1 to 7.0% for GLM whereas the accuracy ranged from 97.0 to 106.4% for PIO and 96.5 to 106.4% for GLM. The mean extraction recovery was found to be 90.2 ± 4.5, 76.8 ± 2.8 and 85.2 ± 5.2% for PIO, GLM and internal standard, respectively. Moreover, PIO and GLM were stable in plasma, up to 30 days of storage at −70 °C and after being subjected to bench top, auto-sampler, and three freeze-thaw cycles. The developed method was applied for preclinical pharmacokinetic studies.

Key words

Antidiabetic drugs - Glimepiride - Pharmacokinetics - Pioglitazone - Rat plasma - Solid phase extraction
 

  • References

  • 1 Karim A, Zhao Z, Slater M, Bradford D, Schuster J, Laurent A. Replicate study design in bioequivalency assessment, pros and cons: bioavailabilities of the antidiabetic drugs pioglitazone and glimepiride present in a fixed-dose combination formulation. J Clin Pharmacol. 2007; 47: 806-16
    PubMedGoogle Scholar
  • 2 Koski RR. Oral Antidiabetic Agents: A Comparative Review. J Pharm Pract. 2004; 17: 39-48
    CrossrefPubMedGoogle Scholar
  • 3 Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001; 111: 10-7
    PubMedGoogle Scholar
  • 4 Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G et al. Metabolic effects of pioglitazone and rosigli-tazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled parallel-group trial. Clin Ther. 2004; 26: 744-54
    CrossrefPubMedGoogle Scholar
  • 5 Derosa G. Pioglitazone plus glimepiride: a promising alternative in metabolic control. Int J Clin Pract. 2007; Suppl 28-36
    PubMedGoogle Scholar
  • 6 Tan M, Johns D, Gonzalez GG, Antunez O, Fabian G, Flores-Lozano F et al. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group trial. Clin Ther. 2004; 26: 680-93
    CrossrefPubMedGoogle Scholar
  • 7 Kanazu T, Okamura N, Yamaguchi Y, Baba T, Koike M. Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. Xenobiotica. 2005; 35: 305-17
    CrossrefPubMedGoogle Scholar
  • 8 Yamamoto T, Suzuki A, Kohno Y, Nagata K, Yamazoe Y. Prediction of drug-drug interactions for AUCoral of high clearance drug from in vitro data: utilization of a microtiter plate assay and a dispersion model. Curr Drug Metab. 2006; 7: 135-46
    CrossrefPubMedGoogle Scholar
  • 9 Singh SS. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab. 2006; 7: 165-82
    Google Scholar
  • 10 Karthik A, Subramanian G, Mallikarjuna Rao C, Bhat K, Ranjithkumar A, Musmade P et al. Simultaneous determination of pioglitazone and glimepiride in bulk drug and pharmaceutical dosage form by RP-HPLC method. Pak J Pharm Sci. 2008; 21: 421-5
    PubMedGoogle Scholar
  • 11 Jain D, Jain S, Jain D, Amin M. Simultaneous estimation of metformin hydrochloride, pioglitazone hydrochloride, and glimepiride by RP-HPLC in tablet formulation. J Chromatogr Sci. 2008; 46: 501-4
    PubMedGoogle Scholar
  • 12 Kolte BL, Raut BB, Deo AA, Bagool MA, Shinde DB. Simultaneous high-performance liquid chromatographic determination of pioglitazone and metformin in pharmaceutical-dosage form. J Chroma-togrSci. 2004; 42: 27-31
    PubMedGoogle Scholar
  • 13 Yao J, Shi YQ, Li ZR, Jin SH. Development of a RP-HPLC method for screening potentially counterfeit anti-diabetic drugs. J Chroma-togrSci. 2007; 853: 254-9
    PubMedGoogle Scholar
  • 14 Deeb ES, Schepers U, Watzig H. Fast HPLC method for the determination of glimepiride, glibenclamide, and related substances using monolithic column and flow program. J High Resolut Chromatogr. 2006; 29: 1571-7
    PubMedGoogle Scholar
  • 15 Khan MA, Sinha S, Vartak S, Bhartiya A, Kumar S. LC determination of glimepiride and its related impurities. J Chroma-togrSci. 2005; 39: 928-43
    PubMedGoogle Scholar
  • 16 Kovarikova P, Klimas J, Dohnal J, Tisovska L. HPLC study of glimepiride under hydrolytic stress conditions. J Chroma-togrSci. 2004; 36: 205-9
    PubMedGoogle Scholar
  • 17 Jedlicka A, Klimes J, Grafnetterova T. Reversed-phase HPLC methods for purity test and assay of pioglitazone hydrochloride in tablets. Pharmazie. 2004; 59: 178-82
    PubMedGoogle Scholar
  • 18 Radhakrishna T, Sreenivas RD, Om RG. Determination of pioglitazone hydrochloride in bulk and pharmaceutical formulations by HPLC and MEKC methods. J Chroma-togrSci. 2002; 29: 593-607
    PubMedGoogle Scholar
  • 19 Bansal G, Singh M, Jindal KC, Singh S. LC-UV-PDA and LC-MS studies to characterize degradation products of glimepiride. Pharm Biomed Anal. 2008; 48: 788-95
    CrossrefPubMedGoogle Scholar
  • 20 Shankar MB, Modi VD, Shah DA, Bhatt KK, Mehta RS, Geetha M et al. Estimation of pioglitazone hydrochloride and metformin hydrochloride in tablets by derivative spectrophotometry and liquid chromatographic methods. J AOAC Int. 2005; 88: 1167-72
    PubMedGoogle Scholar
  • 21 Souri E, Jalalizadeh H, Saremi S. Development and validation of a simple and rapid hplc method for determination of pioglitazone in human plasma and its application to a pharmacokinetic study. J Chromatogr Sci. 2008; 46: 809-12
    PubMedGoogle Scholar
  • 22 Sripalakit P, Neamhom P, Saraphanchotiwitthaya A. High-performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 843: 164-9
    PubMedGoogle Scholar
  • 23 Venkatesh P, Harisudhan T, Choudhury H, Mullangi R, Srinivas NR. Simultaneous estimation of six anti-diabetic drugs–glibenclamide, gliclazide, glipizide, pioglitazone, re-paglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay. Biomed Chromatogr. 2006; 20: 1043-8
    CrossrefPubMedGoogle Scholar
  • 24 Lin ZJ, Ji W, Sai-Krieger D, Shum L. Simultaneous determination of pioglitazone and its two active metabolites in human plasma by LC-MS/MS. J Pharm Biomed Anal. 2003; 33: 101-8
    CrossrefPubMedGoogle Scholar
  • 25 Xue YJ, Turner KC, Meeker JB, Pursley J, Arnold M, Unger S. Quantitative determination of pioglitazone in human serum by direct-injection high-performance liquid chromatography mass spectrometry and its application to a bioequi-valence study. J Chroma-togrSci. 2003; 795: 215-26
    PubMedGoogle Scholar
  • 26 Milena G, Ramirez G, Velasquez O, Perez M, Restrepo P. Validation of analytical method for the determination of glimepiride in human plasma by HPLC/UV with addition standard using glibenclamide as an internal standard. Arch Pharm (Weinheim). 2005; 46: 411-27
    PubMedGoogle Scholar
  • 27 Salem II, Idrees J, Al Tamimi JI. Determination of glimepiride in human plasma by liquid chromatography-electro-spray ionization tandem mass spectrometry. J Chroma-togrSci. 2004; 799: 103-9
    PubMedGoogle Scholar
  • 28 Chakradhar L, Kallem R, Karthik A, Sundari BT, Ramesh S, Mullangi R et al. A rapid and highly sensitive method for the determination of glimepiride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pre-clinical pharmacokinetic study. Biomed Chromatogr. 2008; 22: 58-63
    CrossrefPubMedGoogle Scholar
  • 29 Mistri HN, Jangid AG, Shrivastav PS. Liquid chromatography tandem mass spectrometry method for simultaneous determination of antidiabetic drugs metformin and glybur-ide in human plasma. J Pharm Biomed Anal. 2007; 45: 97-106
    CrossrefPubMedGoogle Scholar
  • 30 Pistos C, Koutsopoulou M, Panderi I. Improved liquid chromatographic tandem mass spectrometric determination and pharmacokinetic study of glimepiride in human plasma. Biomed Chromatogr. 2005; 19: 394-401
    CrossrefPubMedGoogle Scholar
  • 31 Ho EN, Yiu KC, Wan TS, Stewart BD, Watkins KL. Detection of anti-diabetics in equine plasma and urine by liquid chromatography-tandem mass spectrometry. J Chroma-togrSci. 2004; 811: 65-73
    PubMedGoogle Scholar
  • 32 Zhong WZ, Lakings DB. Determination of pioglitazone in dog serum using solid-phase extraction and high-performance liquid chromatography with ultraviolet (229 nm) detection. J Chroma-togrSci. 1989; 490: 377-85
    PubMedGoogle Scholar
  • 33 Zhong WZ, Williams MG. Simultaneous quantitation of pioglitazone and its metabolites in human serum by liquid chromatography and solid phase extraction. J Pharm Biomed Anal. 1996; 14: 465-73
    CrossrefPubMedGoogle Scholar
  • 34 Yamashita K, Murakami H, Okuda T, Motohashi M. High-performance liquid chromatographic determination of pioglitazone and its metabolites in human serum and urine. J Chroma-togrSci. 1996; 677: 141-6
    PubMedGoogle Scholar
  • 35 Song YK, Maeng JE, Hwang HR, Park JS, Kim BC, Kim JK et al. Determination of glimepiride in human plasma using semi-microbore high performance liquid chromatography with column-switching. J Chroma-togrSci. 2004; 810: 143-9
    PubMedGoogle Scholar
  • 36 Lehr KH, Damm P. Simultaneous determination of the sul-phonylurea glimepiride and its metabolites in human serum and urine by high-performance liquid chromatography after pre-column derivatization. J Chromatogr. 1990; 526: 497-505
    CrossrefPubMedGoogle Scholar
  • 37 Choi JS, Burm JP. Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapa-mil, in rats. Arch Pharm Res. 2008; 31: 1200-4
    CrossrefPubMedGoogle Scholar
  • 38 Umathe SN, Dixit PV, Kumar V, Bansod KU, Wanjari MM. Quercetin pretreatment increases the bioavailability of pioglitazone in rats: involvement of CYP3A inhibition. Bio-chem Pharmacol. 2008; 75: 1670-6
    CrossrefPubMedGoogle Scholar
  • 39 Shen Z, Reed JR, Creighton M, Liu DQ, Tang YS, Hora DF et al. Identification of novel metabolites of pioglitazone in rat and dog. Xenobiotica. 2003; 33: 499-509
    CrossrefPubMedGoogle Scholar
  • 40 Guidance for industry: Bioanalytical Method Validation [Internet]. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). [May 2001]. Available from: wwwlfda.gov/cderlguidancelindex.htm
    PubMed
  • 41 European Public Assessment Report (EPAR) by the European Medicines Agency (EMA), [Internet]. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/avaglim/067506en6.pdf
    PubMed